RPG Life Sciences Limited – Investor Update (April 29 2026)

Key Highlights

• Financial Results: FY2025‑26 revenue Rs 70,752 lakhs (+8% YoY); net profit Rs 11,517 lakhs (down from Rs 18,324 lakhs FY2024‑25). EPS fell to Rs 69.64 from Rs 110.80.
• Dividend: Board recommends a final dividend of Rs 24 per share (300% of face value), payable within 30 days of AGM approval.
• Board Change: Dr. Pratit Samdani appointed as an additional non‑executive independent director (5‑year term).
• Cash Position: Cash & cash equivalents surged to Rs 15,046 lakhs (vs Rs 2,870 lakhs last year) driven by a Rs 3,137 lakhs insurance settlement for a fire incident at the Navi Mumbai API plant.
• Debt: Long‑term borrowings of Rs 2,000 lakhs added; total liabilities rose to Rs 18,781 lakhs.
• Exceptional Items:
  • Insurance claim net gain Rs 2,475 lakhs for FY2025‑26.
  • Impact of new labour codes: additional provision Rs 1,169 lakhs.
  • Write‑off of intangible assets under development: Rs 916 lakhs.
• Strategic Move: Approval to transfer the API division to wholly‑owned subsidiary RPG Active Pharma Ltd. – pending regulatory consents.

Financial Analysis

• Revenue Growth: +8% YoY, supported by higher sales volume and price realization.
• Profitability Pressure: Net profit margin fell from ~28% to ~16% due to higher material costs, increased employee benefit expenses, and one‑off charges.
• Liquidity: Strong cash generation (operating cash flow Rs 5,650 lakhs) and cash balance improve short‑term solvency.
• Leverage: Debt‑to‑equity rose to ~0.31, reflecting new borrowings for working capital and capital expenditures.

Strategic Implications

• Dividend Policy: The 300% payout underscores a shareholder‑friendly stance but may limit retained earnings for reinvestment.
• API Division Transfer: Could streamline the business, allowing the parent to focus on higher‑margin segments; however, execution risk remains until approvals are secured.
• Regulatory Impact: New labour codes increase cost base; management is monitoring further rule‑making.

Risks & Opportunities

• Risks: Declining profitability, higher leverage, dependence on one‑off insurance proceeds, pending regulatory approvals for the API transfer, and potential further labour‑related cost escalations.
• Opportunities: Improved cash position, dividend yield, revenue growth trajectory, and possible operational efficiencies post‑API divestiture.

Investor Takeaway RPG Life Sciences shows a mixed picture: robust revenue and cash generation paired with weaker earnings and rising debt. The generous dividend and strategic restructuring offer upside, but investors should watch profit recovery, debt servicing, and the completion of the API division transfer.